Medtronic Begins U.S. Study of Drug-Eluting Stents to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
28
Medtronic Begins U.S. Study of Drug-Eluting Stents to Evaluate Treatment of Bifurcation Lesions in Patients with Coronary Artery Disease

Medtronic Received IDE Approval from FDA to Generate Clinical Evidence with Resolute Onyx DES to Support Future Application for Expanded Indication in U.S.

DUBLIN - May 16, 2018 - Medtronic plc (NYSE: MDT) today announced the initiation of a clinical study in the U.S. to assess the safety and efficacy of drug-eluting stents (DES) for the treatment of bifurcation lesions, which account for approximately 20 percent of all percutaneous coronary interventions (PCI). 1  The Bifurcation Cohort, part of the RESOLUTE ONYX Post-Approval Study, will include patients with coronary artery disease (CAD) receiving the Resolute Onyx(TM) DES in sizes ranging from 2.0 mm - 5.0 mm in diameter. The Resolute Onyx DES is not approved for the treatment of bifurcation lesions in the U.S.

Bifurcation lesions occur when plaque builds up around the junction of two coronary arteries - where one branches off another. These lesions are considered challenging to treat because of anatomical variations in the vessels and the difficulty associated with reaching the side branches. Treatment of bifurcation lesions are commonly associated with lower success rates and increased rates of long-term adverse cardiac events. 1

"Patients with bifurcation lesions present a unique challenge for interventional cardiologists. This study will help us evaluate these patients in a controlled setting, which will help expand our knowledge base," said Matthew J. Price, M.D., interventional cardiologist at Scripps Clinic in La Jolla, Calif., and national principal investigator of the Bifurcation Cohort of the RESOLUTE ONYX Post-Approval Study. "The unique design of Resolute Onyx DES may be well-suited to treat bifurcation lesions in a wide range of vessel sizes."

The Resolute Onyx DES platform is the first-and-only DES to feature Core Wire Technology, an evolution of Continuous Sinusoid Technology (CST). CST is a unique Medtronic method of stent manufacturing, which involves forming a single strand of cobalt alloy wire into a sinusoidal wave to construct a stent. Core Wire Technology enables thinner struts while maintaining structural strength and visibility.

The multi-center, single-arm study intends to enroll 250 patients with bifurcation lesions from 30 sites in the United States and Europe. The primary endpoint is target vessel failure (TVF) at 12 months. Study participants will be followed for three years and receive regular follow-up health assessments. Data from the study will be used to support an application for an indication expansion to include bifurcation lesions for the Resolute Onyx DES from the U.S. Food and Drug Administration (FDA).

"As a leader in next-generation coronary stent technology, we continue to invest in generating robust clinical evidence to address unmet needs in interventional cardiology," said Dave Moeller, vice president and general manager of the Coronary and Renal Denervation business, which is part of the Cardiac and Vascular Group at Medtronic. "We look forward to working with participating centers to begin enrolling patients in this important study."

Resolute Onyx DES received CE ( Conformité Européene ) Mark in September 2014 and FDA approval in April 2017. Resolute Onyx DES is currently indicated in the United States for improving coronary luminal diameters in patients, including those with diabetes mellitus, with symptomatic ischemic heart disease due to de novo lesions of length <= 35 mm in native coronary arteries with reference vessel diameters of 2.0 mm to 5.0 mm.

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.

About Medtronic Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 84,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results .

- end -

1  Sawaya, F., et. al. Contemporary approach to coronary bifurcation lesion treatment. Journal of the American College of Cardiology . September 2016; 18: 1861-1878. http://interventions.onlinejacc.org/content/9/18/1861

 

 

Contacts: Joey Lomicky Public Relations +1-763-526-2494 Ryan Weispfenning Investor Relations +1-763-505-4626

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 514

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 330

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 391

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 182

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 90

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 638

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 225

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 350

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading

Top 5 Most Recently Viewed Articles

Investing in Kinross Gold: A Decade of Growth Analysis

Updated Category News Views 173

Investing in Kinross Gold: A Decade of Growth Kinross Gold (NYSE: KGC), an influential player in the mining industry, has showcased a remarkable performance over the past decade. With an impressive annualized return of 28.15% that exceeds market benchmarks by 15.29%, investors have much to consider regarding the potential of this gold mining giant. The Impact of...

Continue Reading
Chagee Holdings Limited Reports Robust Financial Growth in Q2 2025

Updated Category News Views 391

Chagee Holdings Limited Shows Impressive Growth in Q2 2025 Chagee Holdings Limited (NASDAQ: CHA), a prominent player in the premium tea drinks sector, has reported impressive unaudited financial results for the second quarter of the financial year. The company, renowned for its innovative approach to freshly-made tea drinks, has made significant strides as it continues to...

Continue Reading
Recent Notification on Major Holdings of RENEWI PLC

Updated Category News Views 149

Understanding Major Holdings in RENEWI PLC Investors and stakeholders often seek clarity on significant holdings within companies. This not only shapes perceptions but also influences future decisions and strategies. RENEWI PLC has recently documented changes regarding its holdings and the requirements for notifying stakeholders. This disclosure is crucial for those...

Continue Reading
Gold Port Corporation Expands Private Placement Funding

Updated Category News Views 244

Gold Port Corporation Increases Private Placement to Meet Demand Gold Port Corporation (CSE: GPO) is excited to announce an increase in its non-brokered private placement as a response to significant investor interest. Originally set to raise $1,500,000 through the sale of 20,000,000 units at a price of $0.075 per unit, the company is now keen on maximizing this...

Continue Reading
Ensemble Enhances Patient Care with Strategic Partnership

Updated Category News Views 83

Ensemble made headlines by teaming up with Mary Washington Healthcare (MWHC) in a move that was supposed to revolutionize healthcare services. Back then, the talk was all about boosting financial performance and enhancing patient experiences through some fancy technology. Traders kept an eye on this partnership, pondering whether it could be more than just corporate...

Continue Reading